SY-1425 May Work in Combo with Approved Therapies in Leukemia Patients, Others with Blood Disorders
News
Preclinical data on SY-1425, Syros Pharmaceuticals’ selective retinoic acid receptor alpha (RARα) agonist, suggest this is a promising treatment to be used in combination with Vidaza (azaciditine), a standard of ... Read more